(2S,4S)-4-methoxy-1,2-pyrrolidinedicarboxylic acid 1,2-bis(phenylmethyl ester) | 132592-00-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4S)-4-methoxy-1,2-pyrrolidinedicarboxylic acid 1,2-bis(phenylmethyl ester)
• 英文别名: dibenzyl (2S,4S)-4-methoxypyrrolidine-1,2-dicarboxylate
• CAS: 132592-00-8
• 化学式: C₂₁H₂₃NO₅
• 分子量: 369.417
• InChiKey: BLHCPERPTGCVCS-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲醇 、 (2S,4S)-4-methoxy-1,2-pyrrolidinedicarboxylic acid 1,2-bis(phenylmethyl ester) 在 四乙基对甲苯磺酸铵 作用下， 以5%的产率得到(2S,4S)-4,5-Dimethoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester
  参考文献：
  名称：

  Electrochemical oxidation of proline derivatives: total syntheses of bulgecinine and bulgecin C

  摘要：

  The influence of structure on the efficiency of the electrochemical C-5 oxidation of (2S,4S)-hydroxyproline carbamate esters is presented. Optimum methoxylation was observed with (2S,4S)-4-acetoxy-1,2-pyrrolidine-dicarboxylic acid 2-methyl 1-(2-(trimethylsily)ethyl) ester (19). The corresponding C-5 methoxy derivative 20 was converted into bulgecinine (4) via a stereospecific radical homologation to incorporate the C-5 hydroxymethyl substituent. Bulgecin C (1c) was prepared via a beta-stereoselective glycosidation reaction using a 2-azido-2-deoxy-alpha-D-glucopyranosyl trichloroacetimidate derivative, regiospecific C-4' sulfation, and deprotection.

  DOI：

  10.1021/jo00008a040
• 作为产物：
  描述：

  (2S,4S)-1,2-二苄氧羰基-4-羟基吡咯烷 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以31%的产率得到(2S,4S)-4-methoxy-1,2-pyrrolidinedicarboxylic acid 1,2-bis(phenylmethyl ester)
  参考文献：
  名称：

  Electrochemical oxidation of proline derivatives: total syntheses of bulgecinine and bulgecin C

  摘要：

  The influence of structure on the efficiency of the electrochemical C-5 oxidation of (2S,4S)-hydroxyproline carbamate esters is presented. Optimum methoxylation was observed with (2S,4S)-4-acetoxy-1,2-pyrrolidine-dicarboxylic acid 2-methyl 1-(2-(trimethylsily)ethyl) ester (19). The corresponding C-5 methoxy derivative 20 was converted into bulgecinine (4) via a stereospecific radical homologation to incorporate the C-5 hydroxymethyl substituent. Bulgecin C (1c) was prepared via a beta-stereoselective glycosidation reaction using a 2-azido-2-deoxy-alpha-D-glucopyranosyl trichloroacetimidate derivative, regiospecific C-4' sulfation, and deprotection.

  DOI：

  10.1021/jo00008a040

文献信息

• [EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DU COMPLÉMENT
  申请人：NOVARTIS AG

  公开号：WO2014002054A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物(I)的方法，用于制造该发明的化合物，并将其用作眼部疾病治疗的补体途径调节剂。本发明还提供了一种药理活性剂的组合和制药组合物。
• [EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS DE PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DES VOIES DU COMPLÉMENT
  申请人：NOVARTIS AG

  公开号：WO2014002057A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement alternative inhibitors for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物，其化学式为I：（I），一种制造本发明化合物的方法，以及其作为眼部疾病治疗的补体替代抑制剂的治疗用途。本发明还提供了一种药理活性剂的组合和一种药物组合物。
• EP2661433B1
  申请人：——

  公开号：EP2661433B1

  公开（公告）日：2017-08-16
• PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
  申请人：Novartis AG

  公开号：EP2867224B1

  公开（公告）日：2017-07-26
• EP2867225B1
  申请人：——

  公开号：EP2867225B1

  公开（公告）日：2017-08-09